Abbvie Inc (ABBV)

$263.20 +6.29 (2.45%)
Market Cap 453.91B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 25.45
Forward PE 18.30
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 7,060,400
Avg Vol 7,014,840
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 84%
Beta 0.30
Analysts Strong Sell
Price Target $264.93

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
StocktwitsNews
StocktwitsNews Jul. 29 at 3:33 AM
SLS Stock Heads For Worst Month In Over 2 Years — But Retail Bulls ‘Hold’ For AML Readout And Buyout Hopes $SLS $ABBV $PFE $MRK https://stocktwits.com/news/equity/markets/sls-retail-bulls-hold-for-aml-readout-buyout-hopes/cZNR022RJRT
5 · Reply
AvatarMoon
AvatarMoon Jul. 29 at 3:00 AM
$ABBV I promised myself to be more disciplined and buy more shares like ABBV - instead of having too many AI memory positions..
0 · Reply
FlockOfSeagulls
FlockOfSeagulls Jul. 29 at 2:50 AM
$ABBV Looks like ABBV being pushed up before earnings so that shorts can take her down on even the slightest of misses. Either that or Abbvie is about to make a transformational acquisition in the hematology space.
0 · Reply
Maxwell_Osgood
Maxwell_Osgood Jul. 28 at 11:13 PM
$ABBV Good one!
0 · Reply
_ProfessorGamma
_ProfessorGamma Jul. 28 at 10:12 PM
$IMMX $IBB $SPCH $JEPQ $ABBV ¢¢¢
1 · Reply
SenefAS
SenefAS Jul. 28 at 8:10 PM
When I post this tweet Genmab was at 25$ now closing at 29$ and average target it’s 37.96$ it’s still not late to be in… Earnings are in 8 days… Tic tac $GMAB $GMAB.CO $ABBV $JNJ
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 28 at 8:08 PM
$SLS Lowlife POS --- why can't any of your short scumbag friends find 1 trial -- just 1 for BAT - that casts doubt on Gps success... BAT was APPROVED in 2018 - and you can't find 1 trial??? - all you lowlife lying about a company working on cancer cures Deserves to Catch a Case of the big C yourselves, or maybe someone you love... would be deserving Karmic justice. $XBI $ABBV
2 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 28 at 6:31 PM
$SLS SLS will be Bought for close to $40B -- will Still allow plenty of Upside for $LLY / $ABBV * Gps Phase 2 MOS for CR1 - First Remission Patients Absent transplant was not yet reached and > 67.6 Months. Dr. K and the MDACC team published Benchmark CR1 MOS of 19 months. Gps > 67.6 VS BAT 19 --- It is NOT COMPLICATED This is a look at the CR1 Market Opportunity: 40,000 Patients a Year in the US/Eu/Japan $300K rev per Patient year 1 / 5 Year Anticipated Dosing.
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 28 at 5:51 PM
$SLS $ABBV Do all the SHORT Lowlife Liars Know - BAT - Aza/VEN FAILED the VIALE-M - Phase 3 Maintenance Trial for CR1 Patients who are Ineligible for Transplant? Yes // You - You dumb as F tool -- do you not get it?
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 28 at 4:23 PM
$SLS Look at this SHORT IDIOT TOOL - Stuck its MEAT into the GRINDER... Dr. Tsirigotis KNOWS --- He absolutely Knows -- treats more REGAL P3 Patients than any other clinician and Stated on the Record - "MOS for patients on BAT is extremely poor, just 5 -7 months" and " I STRONGLY Believe Gps will Reach the Primary Endpoint..." So Many Idiot short tools / retail traders too, getting FLEECED... $ABBV $A
1 · Reply
Latest News on ABBV
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Jul 29, 2026, 3:00 AM EDT - 23 minutes ago

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Genmab, AbbVie provide clarification on Phase 3 EPCORE(R) DLBCL-1 trial

2026-07-23T20:05:43.000Z - 5 days ago

Genmab, AbbVie provide clarification on Phase 3 EPCORE(R) DLBCL-1 trial

GMAB

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Jul 23, 2026, 4:00 PM EDT - 5 days ago

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

GMAB

AbbVie price target raised to $282 from $273 at Canaccord

2026-07-22T10:40:12.000Z - 6 days ago

AbbVie price target raised to $282 from $273 at Canaccord

AbbVie’s Allergan Aesthetics receives approval for Boey in Europe

2026-07-17T12:05:34.000Z - 11 days ago

AbbVie’s Allergan Aesthetics receives approval for Boey in Europe

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Jul 17, 2026, 8:00 AM EDT - 11 days ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

AbbVie price target raised to $260 from $230 at Citi

2026-07-15T10:21:06.000Z - 13 days ago

AbbVie price target raised to $260 from $230 at Citi

SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

Jul 14, 2026, 8:05 AM EDT - 14 days ago

SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

Jul 13, 2026, 5:06 PM EDT - 15 days ago

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

APGE SBIO

AbbVie price target raised to $260 from $230 at UBS

2026-07-13T16:30:09.000Z - 15 days ago

AbbVie price target raised to $260 from $230 at UBS

AbbVie price target raised to $300 from $258 at BMO Capital

2026-07-13T12:27:09.000Z - 15 days ago

AbbVie price target raised to $300 from $258 at BMO Capital

2 ‘Strong Buy’ Dividend Aristocrat Stocks to Grab Right Now for August Payouts

2026-07-10T23:36:54.000Z - 18 days ago

2 ‘Strong Buy’ Dividend Aristocrat Stocks to Grab Right Now for August Payouts

ABT

AbbVie price target raised to $280 from $260 at RBC Capital

2026-07-10T13:10:21.000Z - 18 days ago

AbbVie price target raised to $280 from $260 at RBC Capital

AbbVie price target raised to $276 from $234 at BofA

2026-07-10T10:31:16.000Z - 18 days ago

AbbVie price target raised to $276 from $234 at BofA

AbbVie price target raised to $295 from $260 at Wells Fargo

2026-07-10T10:20:22.000Z - 18 days ago

AbbVie price target raised to $295 from $260 at Wells Fargo

AbbVie price target raised to $280 from $260 at JPMorgan

2026-07-09T12:06:14.000Z - 19 days ago

AbbVie price target raised to $280 from $260 at JPMorgan

AbbVie price target raised to $261 from $249 at Guggenheim

2026-07-09T11:30:42.000Z - 19 days ago

AbbVie price target raised to $261 from $249 at Guggenheim

Buy these quality, low-stress stocks for the summer, says Jefferies

Jul 7, 2026, 11:45 AM EDT - 21 days ago

Buy these quality, low-stress stocks for the summer, says Jefferies

AXP HD LOW MCD NFLX PEP PG

AbbVie says Q2 EPS to include unfavorable impact of 17c

2026-07-06T20:20:39.000Z - 22 days ago

AbbVie says Q2 EPS to include unfavorable impact of 17c

AbbVie sees Q2 adjusted EPS ex-items $3.57-$3.61, consensus $3.77

2026-07-06T20:20:19.000Z - 22 days ago

AbbVie sees Q2 adjusted EPS ex-items $3.57-$3.61, consensus $3.77

AbbVie cuts FY26 adjusted EPS view to $13.91-$14.11 from $14.08-$14.28

2026-07-06T20:20:13.000Z - 22 days ago

AbbVie cuts FY26 adjusted EPS view to $13.91-$14.11 from $14.08-$14.28

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Jul 6, 2026, 1:45 PM EDT - 22 days ago

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

US House committee opens investigation into Merck, AbbVie China drug trials

Jun 30, 2026, 6:02 AM EDT - 4 weeks ago

US House committee opens investigation into Merck, AbbVie China drug trials

MRK

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jun 29, 2026, 4:15 PM EDT - 4 weeks ago

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Jun 29, 2026, 3:10 AM EDT - 4 weeks ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

Jun 29, 2026, 3:00 AM EDT - 4 weeks ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Jun 26, 2026, 4:50 PM EDT - 4 weeks ago

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Healthcare stocks have become a haven for investors ditching tech

Jun 26, 2026, 2:39 PM EDT - 4 weeks ago

Healthcare stocks have become a haven for investors ditching tech

ABSI APGE JNJ LLY MRNA SNY XBI

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 26, 2026, 8:00 AM EDT - 4 weeks ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 4 weeks ago

AbbVie's $11 Billion Immunology Bet

APGE

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

Jun 24, 2026, 8:00 AM EDT - 4 weeks ago

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Jun 23, 2026, 8:00 AM EDT - 5 weeks ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

Jun 23, 2026, 5:00 AM EDT - 5 weeks ago

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Jun 23, 2026, 3:00 AM EDT - 5 weeks ago

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

EC

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

Jun 22, 2026, 10:30 AM EDT - 5 weeks ago

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

CRDO MU APGE

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 5 weeks ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE

AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 5 weeks ago

AbbVie Transcript: M&A announcement

AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 5 weeks ago

AbbVie Slides: M&A announcement

AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 5 weeks ago

AbbVie Press release: M&A announcement

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 5 weeks ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

Jun 22, 2026, 7:06 AM EDT - 5 weeks ago

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

APGE

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 5 weeks ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

Jun 22, 2026, 7:00 AM EDT - 5 weeks ago

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

APGE

AbbVie would gain an experimental eczema drug by buying biotech: report

Jun 20, 2026, 12:11 PM EDT - 5 weeks ago

AbbVie would gain an experimental eczema drug by buying biotech: report

APGE

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

Jun 19, 2026, 11:17 AM EDT - 5 weeks ago

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

APGE

AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 5 weeks ago

AbbVie Declares Quarterly Dividend

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

Jun 16, 2026, 8:00 AM EDT - 6 weeks ago

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Jun 12, 2026, 3:00 AM EDT - 6 weeks ago

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Jun 11, 2026, 7:14 AM EDT - 6 weeks ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ALKS AMGN GILD IBB IHE JNJ KYMR

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

Jun 10, 2026, 11:47 AM EDT - 6 weeks ago

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 10:40 AM EDT - 7 weeks ago

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

Jun 8, 2026, 8:00 AM EDT - 7 weeks ago

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Jun 3, 2026, 7:04 PM EDT - 7 weeks ago

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

Jun 3, 2026, 3:30 AM EDT - 7 weeks ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

BIIB LLY ROP

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Jun 2, 2026, 8:00 AM EDT - 2 months ago

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

May 29, 2026, 8:00 AM EDT - 2 months ago

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

May 27, 2026, 6:18 PM EDT - 2 months ago

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

US FDA approves AbbVie's rare blood cancer drug

May 27, 2026, 3:33 PM EDT - 2 months ago

US FDA approves AbbVie's rare blood cancer drug

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

May 22, 2026, 8:00 AM EDT - 2 months ago

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

May 21, 2026, 6:46 PM EDT - 2 months ago

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

May 21, 2026, 4:10 PM EDT - 2 months ago

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 2:20 PM EDT - 2 months ago

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 2 months ago

AbbVie Transcript: AGM 2026

AbbVie to Present at the Bank of America Securities Healthcare Conference

May 6, 2026, 8:00 AM EDT - 2 months ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

May 5, 2026, 8:05 AM EDT - 3 months ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

IBD

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 3:05 PM EDT - 3 months ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

Big Pharma M&A set for mega year as patent expiries drive deal urgency

May 1, 2026, 10:03 AM EDT - 3 months ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

BMY GILD GSK LLY

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Apr 30, 2026, 3:00 PM EDT - 3 months ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

Apr 30, 2026, 9:00 AM EDT - 3 months ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 3 months ago

AbbVie Earnings Call Transcript: Q1 2026

AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 3 months ago

AbbVie Earnings release: Q1 2026

AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 3 months ago

AbbVie Quarterly report: Q1 2026

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 3 months ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

StocktwitsNews
StocktwitsNews Jul. 29 at 3:33 AM
SLS Stock Heads For Worst Month In Over 2 Years — But Retail Bulls ‘Hold’ For AML Readout And Buyout Hopes $SLS $ABBV $PFE $MRK https://stocktwits.com/news/equity/markets/sls-retail-bulls-hold-for-aml-readout-buyout-hopes/cZNR022RJRT
5 · Reply
AvatarMoon
AvatarMoon Jul. 29 at 3:00 AM
$ABBV I promised myself to be more disciplined and buy more shares like ABBV - instead of having too many AI memory positions..
0 · Reply
FlockOfSeagulls
FlockOfSeagulls Jul. 29 at 2:50 AM
$ABBV Looks like ABBV being pushed up before earnings so that shorts can take her down on even the slightest of misses. Either that or Abbvie is about to make a transformational acquisition in the hematology space.
0 · Reply
Maxwell_Osgood
Maxwell_Osgood Jul. 28 at 11:13 PM
$ABBV Good one!
0 · Reply
_ProfessorGamma
_ProfessorGamma Jul. 28 at 10:12 PM
$IMMX $IBB $SPCH $JEPQ $ABBV ¢¢¢
1 · Reply
SenefAS
SenefAS Jul. 28 at 8:10 PM
When I post this tweet Genmab was at 25$ now closing at 29$ and average target it’s 37.96$ it’s still not late to be in… Earnings are in 8 days… Tic tac $GMAB $GMAB.CO $ABBV $JNJ
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 28 at 8:08 PM
$SLS Lowlife POS --- why can't any of your short scumbag friends find 1 trial -- just 1 for BAT - that casts doubt on Gps success... BAT was APPROVED in 2018 - and you can't find 1 trial??? - all you lowlife lying about a company working on cancer cures Deserves to Catch a Case of the big C yourselves, or maybe someone you love... would be deserving Karmic justice. $XBI $ABBV
2 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 28 at 6:31 PM
$SLS SLS will be Bought for close to $40B -- will Still allow plenty of Upside for $LLY / $ABBV * Gps Phase 2 MOS for CR1 - First Remission Patients Absent transplant was not yet reached and > 67.6 Months. Dr. K and the MDACC team published Benchmark CR1 MOS of 19 months. Gps > 67.6 VS BAT 19 --- It is NOT COMPLICATED This is a look at the CR1 Market Opportunity: 40,000 Patients a Year in the US/Eu/Japan $300K rev per Patient year 1 / 5 Year Anticipated Dosing.
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 28 at 5:51 PM
$SLS $ABBV Do all the SHORT Lowlife Liars Know - BAT - Aza/VEN FAILED the VIALE-M - Phase 3 Maintenance Trial for CR1 Patients who are Ineligible for Transplant? Yes // You - You dumb as F tool -- do you not get it?
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 28 at 4:23 PM
$SLS Look at this SHORT IDIOT TOOL - Stuck its MEAT into the GRINDER... Dr. Tsirigotis KNOWS --- He absolutely Knows -- treats more REGAL P3 Patients than any other clinician and Stated on the Record - "MOS for patients on BAT is extremely poor, just 5 -7 months" and " I STRONGLY Believe Gps will Reach the Primary Endpoint..." So Many Idiot short tools / retail traders too, getting FLEECED... $ABBV $A
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 28 at 4:19 PM
$SLS This is only for the DumbAsF Retail SHORTS --- $ABBV Conducted 3 Large Phase 3 Trials with Aza+VEN that FAILED - the BAT for the SLS Control ARM... FAILED 3 Large AML REMISSION MAINTENANCE TRIALS VIALE-T - Post Transplant Remission Maintenance Trial - FAILED VIALE-M - M for Maintenance -FAILED a CR1 Remission Maintenance Trial ... you dumb as F broke D tools stuck your meat into the Grinder. ahaha... $XBI market offering Major Discounts for the Investment Opportunity of a Lifetime.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 28 at 4:04 PM
$SLS Overall Median Survival of 19 months for AML Patients in First Remission (CR1) on BAT - absent Transplant. Gps Phase 2 MOS for CR2 Patients was 21 months Statistically Significant - Longer - and in an Older (74), ALL MRD+ Patient Set - who Got Less GPS Immunotherapy than the P3 GPS patients have Gotten - just a max of 12 doses in Y1 only, vs 15 in the P3 w indefinite dosing for as long as they remain in remission. - the Patients Not able to Withstand Intensive Treatment - Chemo 7+3 - those Patients on VEN+Aza/Deci or LIT have even worse survival --- Universally understood that a Second Remission Duration is about Half the First ... $ABBV WILL BUY SLS
0 · Reply
Layne_Thomas_Staley
Layne_Thomas_Staley Jul. 28 at 3:42 PM
$GANX $ABBV Bought MTK458 back in 2023 🤔
1 · Reply
kagrawala
kagrawala Jul. 28 at 3:07 PM
$ABBV last time i added this was 134-140 range. First time i bought this was 90. Lowest i grabbed this was 62 ish in covid frenzy. Long ABBV grest management and shareholder friendly team!
1 · Reply
Withermania
Withermania Jul. 28 at 1:58 PM
$PHAT love where this team is at. IQVIA chart looks great, Voquezna on its way to becoming the GI standard of care. The GI ecosystem being built by PHAT is going to be an extremely valuable asset. Wouldn’t be shocked to see $ABBV make a move once profitability commences. Could be this week.
1 · Reply
SuperGreenToday
SuperGreenToday Jul. 27 at 11:59 PM
$ABBV Share Price: $256.92 Contract Selected: Aug 21, 2026 $260 Calls Buy Zone: $5.57 – $6.88 Target Zone: $9.51 – $11.62 Potential Upside: 61% ROI Time to Expiration: 24 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
jerry9269
jerry9269 Jul. 27 at 8:03 PM
$ABBV $MRK $PFE $SLS
1 · Reply
Mike22332233
Mike22332233 Jul. 27 at 8:01 PM
$SLS NEW ACTION ALERT .... Just HOLD UNTIL BO of SLS ... ANY DAY COULD BE THE START OF IT !!!!! …. * 80th event = $18-$22 (Unless CEO stats at 80th that ALL the 46 patients still living are GPS, and then SLS goes into the $70's) * Trial Readout = $55-$75 * First BO Offer = $140-$160 * Final Bidding War BO = $202 * 2 or more of these BP will bid: $MRK, $ABBV, $PFE, BMY, LLY , RHHBY, NVS, AZN * BO winner will be MRK or RHHBY LIKE if you agree with my price targets ..... FOLLOW me 👉 @Mike22332233 to get complete SLS info
2 · Reply
Tom2772
Tom2772 Jul. 27 at 7:32 PM
$OTLK $REGN $ABBV There may be more going on behind the scenes than we know. $OTLK could still be a diamond 💎 in the rough. We may find out soon.
0 · Reply
Conorkenny
Conorkenny Jul. 27 at 7:22 PM
🚨 US MEMORY STOCKS ARE CRASHING $1 Trillion has been wiped out from US stocks in the last 3 hours, and 50% of that came from just 6 memory stocks. US memory stocks are crashing on news that China has begun producing its own DUV chipmaking machines. Investors worry China can now build more chip factories on its own, adding supply and pushing memory chip prices down, exactly the prices that have been driving these stocks higher all year. $CCJ $ABBV $XOM $SKHY
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 27 at 6:28 PM
$SLS $LLY $ABBV When the Imminently DUE P3 Results are Announced - we will see a T1 Trading Halt followed by a Gap up into the $60's or $70's. 400 million Shares Will Trade --- Gps, a revolutionary AML Remission Maintenance Immunotherapy, is getting the FDA Green light to to treat upwards of 50,000 AML Patients and Generate $28B PER YEAR ... This Short Manipulated $2B baby Bio is about to be worth 25 X THAT... Mark this Post. Something Just like what happened at $ABVX is about to Happen Here.
0 · Reply
DidYouReadThis
DidYouReadThis Jul. 27 at 6:13 PM
What’s your favorite western? $OTLK $REGN $NVS $ABBV
0 · Reply